Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the clinical trial is to test how Simvastatin (80mg/day) may decrease attacks
and progression of disease in patients with multiple sclerosis under disease modifying
therapy (DMTs)